Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.

S'inscrire

ADAG Adagene Inc

2,09

0,00 (0,00%)

Avant marché

Dernière mise à jour : 14:46:08

Retardé de 15 minutes

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Adagene (NASDAQ:ADAG)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024

Plus de graphiques de la Bourse Adagene

Adagene (NASDAQ:ADAG)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024

Plus de graphiques de la Bourse Adagene

Actualités Adagene Inc

Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]
Jeudi 7 Novembre 2024 ( il y a 2 semaines) • Edgar (US Regulatory)

Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]
Jeudi 7 Novembre 2024 ( il y a 2 semaines) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Jeudi 7 Novembre 2024 ( il y a 2 semaines) • Edgar (US Regulatory)

Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Soc
Jeudi 7 Novembre 2024 ( il y a 2 semaines) • GlobeNewswire Inc.

Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Mercredi 9 Octobre 2024 ( il y a 1 mois) • GlobeNewswire Inc.

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Mardi 24 Septembre 2024 ( il y a 2 mois) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Lundi 16 Septembre 2024 ( il y a 2 mois) • Edgar (US Regulatory)

Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC
Lundi 16 Septembre 2024 ( il y a 2 mois) • GlobeNewswire Inc.

Adagene to Participate in Investor Conferences in September
Jeudi 29 Août 2024 ( il y a 3 mois) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Jeudi 25 Juillet 2024 ( il y a 4 mois) • Edgar (US Regulatory)

Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update
Jeudi 25 Juillet 2024 ( il y a 4 mois) • GlobeNewswire Inc.

Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September
Vendredi 12 Juillet 2024 ( il y a 4 mois) • GlobeNewswire Inc.

Plus d'articles sur Adagene Inc

Lvmh Moet Hennessy Louis...

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales